Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
09 mai 2023 08h00 HE
|
Phathom Pharmaceuticals
Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristicsMeta-analysis...
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
04 avr. 2023 08h00 HE
|
Phathom Pharmaceuticals
Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarterCombined commercial...
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
08 nov. 2022 17h00 HE
|
Phathom Pharmaceuticals
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to...
Biomerica Reports Fiscal 2022 Year End Results
29 août 2022 16h41 HE
|
Biomerica, Inc.
Revenues increase 162% for fiscal 2022 vs fiscal 2021 Revenues for fiscal Q4 2022 up 403% vs. fiscal Q4 2021 IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the...
Helicobacter Pylori Non-invasive Testing Market Revenue to Cross $800.04Mn, Globally, by 2028 to Growing at 4.4% CAGR – Study by The Insight Partners
24 août 2022 06h00 HE
|
The Insight Partners
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Forecast to 2028 – COVID-19 Impact...
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
01 juin 2022 08h15 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
24 mai 2022 12h15 HE
|
Phathom Pharmaceuticals
Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior maintenance of...
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
17 mai 2022 08h01 HE
|
Phathom Pharmaceuticals
New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori (H. pylori)...
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
12 mai 2022 08h19 HE
|
Biomerica, Inc.
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human...
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
10 mai 2022 08h00 HE
|
Phathom Pharmaceuticals
U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H....